-
公开(公告)号：US20170183391A9
公开(公告)日：2017-06-29
申请号：US15004375
申请日：2016-01-22
Applicant: Amgen Inc.
Inventor： Jeonghoon Sun , Lei-Ting Tony Tam , Mark Leo Michaels , Thomas Charles Boone , Rohini Deshpande , Yue-Sheng Li , Huiquan Han
IPC: C07K14/71
CPC classification number: C07K14/71 , A61K38/00 , C07K14/495
Abstract: The present invention provides stabilized activin IIB receptor polypeptides and proteins capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the stabilized polypeptides and proteins. Compositions and methods for treating muscle-wasting diseases and metabolic disorders are also provided.
-
12.发明授权公开(公告)号：US09493530B2
公开(公告)日：2016-11-15
申请号：US14167662
申请日：2014-01-29
Applicant: AMGEN INC.
Inventor： Edward John Belouski , Murielle Marie Ellison , Agnes Eva Hamburger , Randy Ira Hecht , Yue-Sheng Li , Mark Leo Michaels , Jeonghoon Sun , Jing Xu
CPC classification number: C07K14/50 , A61K38/00 , C07K2319/30
Abstract: The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions. In some embodiments, the FGF21 mutant polypeptide comprises a substitution at position 98, 171 and/or 180.
Abstract translation: 本发明提供编码FGF21突变体多肽，FGF21突变体多肽，包含FGF21突变体多肽的药物组合物的核酸分子，以及使用此类核酸，多肽或药物组合物治疗代谢紊乱的方法。 在一些实施方案中，FGF21突变体多肽包含位置98,171和/或180处的取代。
-
公开(公告)号：US11072640B2
公开(公告)日：2021-07-27
申请号：US15996232
申请日：2018-06-01
Applicant: AMGEN INC.
Inventor： Edward John Belouski , Murielle Marie Ellison , Agnes Eva Hamburger , Randy Ira Hecht , Yue-Sheng Li , Mark Leo Michaels , Jeonghoon Sun , Jing Xu
Abstract: The invention provides methods for treating non-alcoholic steatohepatitis (NASH) using FGF21 mutant polypeptides.
-
公开(公告)号：US20140243503A1
公开(公告)日：2014-08-28
申请号：US14134482
申请日：2013-12-19
Applicant: Amgen Inc.
Inventor： Edward John Belouski , Murielle Marie Ellison , Agnes Eav Hamburger , Randy Ira Hecht , Yue-Sheng Li , Mark Leo Michaels , Jeonghoon Sun , Jing Xu
CPC classification number: C07K14/50 , A61K38/00 , A61K38/1825 , A61K2039/505 , C07K16/18 , C07K2319/30
Abstract: The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.
-
公开(公告)号：US11840558B2
公开(公告)日：2023-12-12
申请号：US17357444
申请日：2021-06-24
Applicant: AMGEN INC.
Inventor： Edward John Belouski , Murielle Marie Ellison , Agnes Eva Hamburger , Randy Ira Hecht , Yue-Sheng Li , Mark Leo Michaels , Jeonghoon Sun , Jing Xu
CPC classification number: C07K14/05 , A61K38/1825 , A61K38/00 , A61K2039/505 , C07K16/18 , C07K2319/30
Abstract: The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.
-
Patent Agency Ranking
公开(公告)号：US11685770B2
公开(公告)日：2023-06-27
申请号：US16388561
申请日：2019-04-18
Applicant: AMGEN INC.
Inventor： Jeonghoon Sun , Lei-Ting Tony Tam , Mark Leo Michaels , Thomas Charles Boone , Rohini Deshpande , Yue-Sheng Li , Huiquan Han
IPC: C07K14/495 , C07K14/71 , A61K38/00
CPC classification number: C07K14/71 , C07K14/495 , A61K38/00
Abstract: The present invention provides stabilized activin IIB receptor polypeptides and proteins capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the stabilized polypeptides and proteins. Compositions and methods for treating muscle-wasting diseases and metabolic disorders are also provided.
-
公开(公告)号：US20210317176A1
公开(公告)日：2021-10-14
申请号：US17357444
申请日：2021-06-24
Applicant: AMGEN INC.
Inventor： Edward John Belouski , Murielle Marie Ellison , Agnes Eva Hamburger , Randy Ira Hecht , Yue-Sheng Li , Mark Leo Michaels , Jeonghoon Sun , Jing Xu
Abstract: The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.
-
公开(公告)号：US09562107B2
公开(公告)日：2017-02-07
申请号：US14285576
申请日：2014-05-22
Applicant: AMGEN INC.
Inventor： Kenneth W. Walker , Yue-Sheng Li , Thomas Charles Boone , George Doellgast , HoSung Min , Jane Talvenheimo , Taruna Arora , Frederick W. Jacobsen
IPC: C07K16/44 , A61K39/395 , C07K16/00 , C07K16/18 , C07K14/435 , C07K14/575 , C07K14/605 , C07K16/24
CPC classification number: C07K16/44 , A61K39/39591 , A61K47/6817 , A61K47/6843 , C07K14/43504 , C07K14/575 , C07K14/605 , C07K14/66 , C07K16/00 , C07K16/18 , C07K16/248 , C07K2317/21 , C07K2317/24 , C07K2317/56 , C07K2317/565 , C07K2317/92 , C07K2317/94 , C07K2319/00 , C07K2319/30 , C07K2319/55
Abstract: Disclosed is an isolated antigen binding protein, such as but not limited to, an antibody or antibody fragment. Also disclosed are pharmaceutical compositions and medicaments comprising the antigen binding protein, isolated nucleic acid encoding it, vectors, host cells, and hybridomas useful in methods of making it. In some embodiments the antigen binding protein comprises one to twenty-four pharmacologically active chemical moieties conjugated thereto, such as a pharmacologically active polypeptide.
-
公开(公告)号：US20160137718A1
公开(公告)日：2016-05-19
申请号：US15004375
申请日：2016-01-22
Applicant: Amgen Inc.
Inventor： Jeonghoon Sun , Lei-Ting Tony Tam , Mark Leo Michaels , Thomas Charles Boone , Rohini Deshpande , Yue-Sheng Li , Huiquan Han
IPC: C07K14/71
CPC classification number: C07K14/71 , A61K38/00 , C07K14/495
Abstract: The present invention provides stabilized activin IIB receptor polypeptides and proteins capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the stabilized polypeptides and proteins. Compositions and methods for treating muscle-wasting diseases and metabolic disorders are also provided.
Abstract translation: 本发明提供稳定的活化素IIB受体多肽和能够结合并抑制活化素A，肌生成抑制素或GDF-11的活性的蛋白质。 本发明还提供能够产生稳定的多肽和蛋白质的多核苷酸，载体和宿主细胞。 还提供了治疗肌肉消瘦疾病和代谢紊乱的组合物和方法。
-
20.发明授权Human anti-IFN-γ neutralizing antibodies as selective IFN-γ pathway inhibitors 有权人抗IFN-γ中和抗体作为选择性IFN-γ途径抑制剂公开(公告)号：US08906371B2
公开(公告)日：2014-12-09
申请号：US13966185
申请日：2013-08-13
Applicant: Amgen, Inc. , Mederex, L.L.C.
Inventor： Andrew A. Welcher , Hilary T. Chute , Yue-Sheng Li , Haichun Huang
IPC: A61K39/395 , C07K16/24 , C07K16/00 , A61K39/00
CPC classification number: C07K16/249 , A61K2039/505 , C07K2317/21 , C07K2317/56 , C07K2317/565 , C07K2317/76
Abstract: This invention provides antibodies that interact with or bind to human interferon-gamma (IFN-γ) and methods for treating IFN-γ mediated diseases by administering a pharmaceutically effective amount of antibodies to IFN-γ. Methods of detecting the amount of IFN-γ in a sample using antibodies to IFN-γ are also provided.
Abstract translation: 本发明提供了与人干扰素-γ（IFN-γ）相互作用或与之结合的抗体以及通过向IFN-γ施用药学上有效量的抗体来治疗IFN-γ介导的疾病的方法。 还提供了使用抗IFN-γ抗体检测样品中IFN-γ量的方法。
-
-
-
-
-
-
-
-
-
Search Results
21
records
(took 0.026 seconds)
